Home
Resources
Publications
Effect of New Thiazolidine Derivatives LPSF/GQ-02 and LPSF/GQ-16 on Atherosclerotic Lesions in LDL Receptor-Deficient Mice (LDLR(-/-))

Effect of New Thiazolidine Derivatives LPSF/GQ-02 and LPSF/GQ-16 on Atherosclerotic Lesions in LDL Receptor-Deficient Mice (LDLR(-/-))

Amanda Karolina Soares E Silva, Dilênia de Oliveira Cipriano Torres, Sura Wanessa Santos Rocha, Fabiana Oliveira dos Santos Gomes, Bruna dos Santos Silva, Mariana Aragão Matos Donato, Catarina Raposo, Ana Célia Oliveira Santos, etc.

Cardiovasc Pathol. Jan-Feb 2013;22(1):81-90.

PMID: 22795892

Abstract:

Background:
Atherosclerotic cardiovascular disease is a chronic inflammatory condition. Thiazolidinediones (TZDs) are used to enhance sensitivity to insulin and have demonstrated a protective effect over a variety of cardiovascular markers and risk factors. Controversially, the TZDs are associated with the development of heart failure. Thus, lines of research have invested in the search for new molecules in order to obtain more selective and less harmful treatment alternatives for the pathogenesis of atherosclerosis and its risk factors.
Methods:
Animals were fed a diet rich in fat for 10 weeks. In the last 2 weeks, animals received either pioglitazone, LPSF/GQ-02, or LPSF/GQ-16 daily through gavage. At the end of the treatment, blood was collected for biochemical analysis and the aortas were dissected for subsequent analyses.
Results:
No changes in the blood lipid profile were found following the use of the drugs in comparison to the control. However, the new thiazolidine derivatives were more efficient in improving insulin resistance in comparison to pioglitazone and the control group. Morphometric analyses revealed that neither pioglitazone nor LPSF/GQ16 led to satisfactory effects over atherosclerosis. However, LPSF/GQ-02 led to a reduction in area of the atherosclerotic lesions. Ultrastructural analyses revealed extensive degeneration of the endothelium and an increase in apoptotic cells in the subendothelial space following the use of pioglitazone and LPSF/GQ-16. However, LPSF/GQ-02 caused minimal cell alterations in the aortic endothelium. Regarding markers, endothelial nitric oxide synthase (eNOS) and matrix metalloproteinase 9 (MMP-9), LPSF/GQ-16, and pioglitazone exerted similar effects, increasing the expression of MMP-9, and had no effect on the expression of eNOS compared with the control group. On the other hand, LPSF/GQ-02 was effective in reducing the expression of MMP-9 and increased eNOS significantly.
Conclusions:
The results suggest that the new thiazolidine derivative LPSF/GQ-02 is a promising candidate for the treatment of atherosclerosis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP870554602	LPSF/GQ-02		870554-60-2	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: